Results 1 to 10 of about 3,406 (148)

Real-world efficacy and safety of Tenecteplase versus Alteplase in acute ischemic stroke: a propensity score-matched analysis [PDF]

Frontiers in Neurology
BackgroundReal-world evidence comparing Tenecteplase and Alteplase for acute ischemic stroke (AIS) remains limited. This study aimed to evaluate the comparative efficacy and safety of these thrombolytic agents in an unselected patient cohort.MethodsThis ...
Peng Zhang, Liangyun Sun, Liangxue Wang
doaj   +2 more sources

Tenecteplase, 0.4 mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR‐TEST and NOR‐TEST 2A

Journal of the American Heart Association, 2023
Background The optimal dose of tenecteplase in acute ischemic stroke remains to be defined. We present a pooled analysis of the 2 NOR‐TESTs (Norwegian Tenecteplase Stroke Trials) exploring the efficacy and safety of tenecteplase, 0.4 mg/kg.
Nicola Logallo, Lars Thomassen, Vojtech Novotny   +2 more
exaly   +3 more sources

Thrombus Migration After Tenecteplase Versus Alteplase in Acute Large Vessel Occlusion [PDF]

Journal of Stroke
Background and Purpose In patients with large vessel occlusion (LVO), intravenous thrombolysis (IVT) frequently alters thrombus location; however, the clinical impact of this phenomenon remains unclear.
Lu Wang, Fuxia Yang, Xiao Wu, Lulan Li, Xueqiao Jiao, Fangfang Zhang, Fengyuan Che, Hongxing Han, Weidong Liu, Peifu Wang, Xuesong Li, Junfeng Shi, Jia Liu, Xunming Ji, Xiuhai Guo   +14 more
doaj   +2 more sources

Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke

Journal of the American Heart Association
Although intravenous thrombolysis with alteplase remains the primary treatment for acute ischemic stroke, tenecteplase has shown potential advantages over alteplase.
Marc Fisher, Yunyun Xiong, Liyuan Wang   +2 more
exaly   +3 more sources

Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials

Annals of Medicine
Objectives Tenecteplase, a modified variant of alteplase with greater fibrin specificity and longer plasma half-life, may have better efficacy and safety than alteplase in patients with acute ischemic stroke (AIS).
Xiaofeng Ping
exaly   +3 more sources

Clinical benefit of tenecteplase despite failed recanalization in late-window ischemic stroke: a post hoc analysis of the TRACE-3 trial [PDF]

BMC Medicine
Background The TRACE-3 trial established the efficacy of intravenous tenecteplase for patients with acute ischemic stroke and large vessel occlusion in the late time window.
Zhengzhao Lu, Ziran Wang, Aoming Jin, Fengyuan Che, Lihua Wang, Li Zhou, Hongguo Dai, Xintong Liu, Zhixin Cao, Liyuan Wang, Manjun Hao, Wanxing Ye, Yunyun Xiong, Yongjun Wang   +13 more
doaj   +2 more sources

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials

Frontiers in Neurology, 2023
BackgroundThe optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS) has yet to be established. Therefore, we included the latest randomized controlled trials (RCT) to assess the efficacy and safety of different doses of tenecteplase ...
Huo Liang, Xue Wang, Xuemei Quan, Shijian Chen, Bin Qin, Shuolin Liang, Qiuhui Huang, Jian Zhang, Zhijian Liang   +8 more
doaj   +1 more source

Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study

Medicina, 2022
Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase.
Agnete Teivane, Kristaps Jurjāns, Jānis Vētra, Jekaterina Grigorjeva, Karlis Kupcs, Rytis Masiliūnas, Evija Miglāne   +6 more
doaj   +1 more source

Abstract 267: A Bibliometric Analysis of Tenecteplase Research Utilizing a Commonly Used Citation Index

Stroke: Vascular and Interventional Neurology, 2023
Introduction Tenecteplase is increasingly being used as a first‐line treatment for acute ischemic stroke after several randomized studies demonstrated its safety and efficacy, resulting in a massive increase in the number of published studies on this ...
Brendan Huang
doaj   +1 more source

Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?

Western Journal of Emergency Medicine, 2020
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as ...
Tony Zitek, Ramsey Ataya, Isabel Brea
doaj   +1 more source